News

Awarding laughter… check out these past Ig Nobel Prize winners.

From the efficacy of adjunctive TMS for treatment-resistant major depression to a look at adult ADHD, here are highlights from the week in Psychiatric Times.

The presentation of schizophrenia differs significantly between men and women. Here's what you need to know.

What is new in research on psychiatric care for Latinx patient populations?

September 15 to October 15 is Hispanic Heritage Month. To celebrate, here’s a look at some recent coverage in Psychiatric Times® on how clinicians can improve psychiatric care for Latinx patients.

Arts and psychiatry: better at collaboration than most.

What 10 things do you need to know before entering a job interview?

As we say goodbye to summer…

What astonishes you?

"Collaborative care quality initiatives may have become an insurance industry buzzword, but the true spirit of collaborating to save lives has always lived within clinicians."

An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.

Let’s take another look at telepsychiatry.

Adjunctive rTMS for treatment-resistant depression? Researchers performed a meta-analysis of 19 randomized sham-controlled trials.

Have you registered for the 2023 Annual Psychiatric Times World CME Conference?

Have you ever had a patient die by suicide?

"The history of psychiatry is a history of fads in theory, diagnosis, and treatment. Such rapid shifts in conceptualization—such as the emergence of the concept of adult ADHD—almost always warrant informed critical examination."

“Our findings might inform PTSD pathology, treatment plans, and future disaster-response strategies.”

Never forget.

Investigators noted sustained improvement in depressive symptoms for up to 6.5 years.

The relationship of this key symptom of major depressive disorder and patient burden is not well understood. These two posters covered it.

“Among employed adults with TRD, esketamine nasal spray treatment was associated with significantly larger improvements in WPL and related costs compared to quetiapine extended-release treatment.”

Today is World Suicide Prevention Day. Take a look at our latest content on suicide.

These 3 posters covered the efficacy and safety of paliperidone palmitate in patients with schizophrenia.

From cannabis use disorder and schizophrenia to social media use and youth mental health, here are highlights from the week in Psychiatric Times.

What is new in research on attention-deficit/hyperactivity disorder?

Integrated models of care offer real time solutions by enabling primary care to identify and address behavioral health concerns through routine screening and early intervention more efficiently. Learn more here.

In honor of National Suicide Prevention Week next week, let’s talk about suicide.

Exploring the connection between trauma and the etiology of schizophrenia, and the ways this connection was historically interpreted in the case of the Genain quadruplets.

How can augmenting conventional antidepressants with creatine monohydrate help patients with depression?

Climate activism: how can you be involved as a mental health clinician?